Inventor · disambiguated record
Kevin J. Wilson
Also filed as: WILSON KEVIN · WILSON KEVIN J
40 granted patents·26 pending applications·369 citations·filing 2003–2024
98Inventor score
Files withBLUEPRINT MEDICINES CORP25MERCK SHARP & DOHME13FOGHORN THERAPEUTICS INC9WILSON KEVIN3GRIMM JONATHAN2
Top patents by PatentIndex Score
66 records- 0198US10030005B2Inhibitors of RETBLUEPRINT MEDICINES CORP·Filed 2016·Granted Jul 24, 2018·38 cites·30 claims
- 0297US11279688B2Inhibitors of RETBLUEPRINT MEDICINES CORP·Filed 2020·Granted Mar 22, 2022·5 cites·2 claims
- 0397US10000496B2Compositions useful for treating disorders related to kit and PDGFRBLUEPRINT MEDICINES CORP·Filed 2016·Granted Jun 19, 2018·32 cites·54 claims
- 0497US9994575B2Compositions useful for treating disorders related to kitBLUEPRINT MEDICINES CORP·Filed 2015·Granted Jun 12, 2018·32 cites·20 claims
- 0597US9944651B2Compositions useful for treating disorders related to kitBLUEPRINT MEDICINES CORP·Filed 2017·Granted Apr 17, 2018·33 cites·24 claims
- 0697US9200002B2Compositions useful for treating disorders related to KITHODOUS BRIAN L·Filed 2014·Granted Dec 1, 2015·49 cites·6 claims
- 0796US11827642B2Compositions useful for treating disorders related to KITBLUEPRINT MEDICINES CORP·Filed 2022·Granted Nov 28, 2023·2 cites·6 claims
- 0896US10807985B2Compositions useful for treating disorders related to kitBLUEPRINT MEDICINES CORP·Filed 2018·Granted Oct 20, 2020·7 cites·1 claims
- 0996US10227329B2Compounds useful for treating disorders related to RETBLUEPRINT MEDICINES CORP·Filed 2017·Granted Mar 12, 2019·19 cites·21 claims
- 1095US10584114B2Inhibitors of RETBLUEPRINT MEDICINES CORP·Filed 2018·Granted Mar 10, 2020·13 cites·3 claims
- 1195US10183928B2Inhibitors of RETBLUEPRINT MEDICINES CORP·Filed 2017·Granted Jan 22, 2019·13 cites·47 claims
- 1293US11718602B2EGFR inhibitorsBLUEPRINT MEDICINES CORP·Filed 2022·Granted Aug 8, 2023·2 cites·8 claims
- 1393US10233186B2Inhibitors of activin receptor-like kinaseBLUEPRINT MEDICINES CORP·Filed 2017·Granted Mar 19, 2019·16 cites·56 claims
- 1493US7981874B2Phosphorus derivatives as histone deacetylase inhibitorsMERCK SHARP & DOHME·Filed 2007·Granted Jul 19, 2011·21 cites·17 claims
- 1590US10669277B2Inhibitors of activin receptor-like kinaseBLUEPRINT MEDICINES CORP·Filed 2019·Granted Jun 2, 2020·9 cites·17 claims
- 1687US2024317757A1Compositions useful for treating disorders related to kitBLUEPRINT MEDICINES CORP·Filed 2023·Application pending·0 cites
- 1786US12139487B2Compounds and uses thereofFOGHORN THERAPEUTICS INC·Filed 2023·Granted Nov 12, 2024·1 cites·102 claims
- 1886US7381725B2Pyridazine derivatives as ligands for GABA receptorsMERCK SHARP & DOHME·Filed 2003·Granted Jun 3, 2008·17 cites·4 claims
- 1985US7834034B2Benzothiophene derivativesMERCK SHARP & DOHME·Filed 2006·Granted Nov 16, 2010·9 cites·11 claims
- 2085US2024417386A1Inhibitors of retRIGEL PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 2183US11634422B2Inhibitors of activin receptor-like kinaseBLUEPRINT MEDICINES CORP·Filed 2020·Granted Apr 25, 2023·1 cites·30 claims
- 2281US9023865B2Compounds that are ERK inhibitorsLIM JONGWON·Filed 2012·Granted May 5, 2015·4 cites·20 claims
- 2380US12441726B2Compounds and uses thereofFOGHORN THERAPEUTICS INC·Filed 2021·Granted Oct 14, 2025·1 cites·40 claims
- 2480US2025289801A1Egfr inhibitorsBLUEPRINT MEDICINES CORP·Filed 2024·Application pending·0 cites
- 2579US9096559B24-carboxybenzylamino derivatives as histone deacetylase inhibitorsHARRINGTON PAUL·Filed 2013·Granted Aug 4, 2015·5 cites·3 claims
- 2679US8367706B2Inhibitors of janus kinasesMERCK SHARP & DOHME·Filed 2008·Granted Feb 5, 2013·5 cites·8 claims
- 2779US8344144B2Inhibitors of Janus kinasesMERCK SHARP & DOHME·Filed 2009·Granted Jan 1, 2013·5 cites·6 claims
- 2879US8158825B2Modified malonate derivativesGRIMM JONATHAN·Filed 2006·Granted Apr 17, 2012·9 cites·17 claims
- 2977US7772238B2Benzothiophene hydroxamic acid derivativesMERCK SHARP & DOHME·Filed 2006·Granted Aug 10, 2010·4 cites·15 claims
- 3077US2022315560A1Inhibitors of retBLUEPRINT MEDICINES CORP·Filed 2022·Application pending·0 cites
- 3176US8415346B2Inhibitors of Janus kinasesALTMAN MICHAEL·Filed 2009·Granted Apr 9, 2013·4 cites·8 claims
- 3274US8420695B2Inhibitors of janus kinasesWILSON KEVIN·Filed 2009·Granted Apr 16, 2013·4 cites·8 claims
- 3374US2021284645A1Compositions useful for treating disorders related to kitBLUEPRINT MEDICINES CORP·Filed 2020·Application pending·0 cites
- 3473US6969716B25-phenyl[1,2,4]triazines as ligands for GABA-A α2/α3 receptors for treating anxiety or depressionMERCK SHARP & DOHME·Filed 2004·Granted Nov 29, 2005·6 cites·10 claims
- 3572US12172983B2EGFR inhibitorsBLUEPRINT MEDICINES CORP·Filed 2021·Granted Dec 24, 2024·0 cites·21 claims
- 3672US7468393B2Diarylsulfones as 5-HT2A antagonistsMERCK SHARP & DOHME·Filed 2007·Granted Dec 23, 2008·1 cites·17 claims
- 3771US2025066354A1Compounds and uses thereofFOGHORN THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3867US8168658B2Inhibitors of histone deacetylaseGRIMM JONATHAN B·Filed 2007·Granted May 1, 2012·2 cites·7 claims
- 3964US9745307B2Compounds that are ERK inhibitorsMERCK SHARP & DOHME·Filed 2014·Granted Aug 29, 2017·0 cites·7 claims
- 4063US10759805B2Compounds that are ERK inhibitorsMERCK SHARP & DOHME·Filed 2018·Granted Sep 1, 2020·0 cites·14 claims
- 4162US2025304596A1Pyrazine derivatives and uses thereofFOGHORN THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 4261US11040979B2Substituted pyrrolo[1,2-b]pyridazines for treating disorders related to KIT and PDGFRBLUEPRINT MEDICINES CORP·Filed 2018·Granted Jun 22, 2021·0 cites·9 claims
- 4360US10065967B2Compounds that are ERK inhibitorsMERCK SHARP & DOHME·Filed 2017·Granted Sep 4, 2018·0 cites·15 claims
- 4460US2024382483A1Heterocyclic egfr inhibitors for use in the treatment of cancerBLUEPRINT MEDICINES CORP·Filed 2022·Application pending·0 cites
- 4558US2024299387A1Heterocyclic egfr inhibitors for use in the treatment of cancerBLUEPRINT MEDICINES CORP·Filed 2022·Application pending·0 cites
- 4658US2024308981A1Heterocyclic egfr inhibitors for use in the treatment of cancerBLUEPRINT MEDICINES CORP·Filed 2022·Application pending·0 cites
- 4758US2024300946A1Egfr inhibitorsBLUEPRINT MEDICINES CORP·Filed 2022·Application pending·0 cites
- 4857US2024376121A1Compounds and uses thereofFOGHORN THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4955US9493441B2Acyclic cyanoethylpyrazoles as janus kinase inhibitorsBRUBAKER JASON·Filed 2012·Granted Nov 15, 2016·0 cites·10 claims
- 5055US2023149414A1Compounds and uses thereofFOGHORN THERAPEUTICS INC·Filed 2021·Application pending·0 cites
Showing the top 50 of 66 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Kevin J. Wilson files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →